Crown Bioscience Expands Genomics and Next Generation Sequencing (NGS) Capabilities To Streamline Translational Biomarker Discovery Workflows
Crown Bioscience, a JSR Life Sciences company, today announced the expansion of their state-of-the-art NGS capabilities, together with the launch of proprietary NGS panel services, providing increased opportunities for pharmaceutical partners to better understand drug mechanisms of action (MOA) and to develop predictive biomarkers for their investigational drug candidates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005802/en/
(Graphic: Business Wire)
The newly built, comprehensive suite of NGS capabilities provides clients with a streamlined multi-omics workflow of high-quality services, enabling full genomic understanding, including global gene expression, mutations, and genomic structures. This is a significant addition to CrownBio’s current preclinical and translational services, allowing clients greater insight into disease mechanisms, drug MOAs, and responder patient populations, to ultimately accelerate successful development of effective therapies.
The expanded services have been established at the Company’s Center of Translational Science in Suzhou, China, to meet increased client demand for whole genome sequencing (WGS), including Illumina’s Novaseq 6000 and BGI’s MGISEQ-2000 second generation sequencing platform. PacBio’s third generation Sequel Ⅱ sequencing platform allows for high throughput, high accuracy long-read NGS, and Bionano’s Saphyr® Genome Imaging enables large structural variant analysis and genome mapping. Comprehensive data analysis pipelines have also been built, together offering highly sensitive genome assembly and discovery algorithms.
“With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers,” said Henry Li, PhD, chief scientific officer at CrownBio. “This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments.”
In addition to the validated commercial platforms, CrownBio has also developed various powerful biomedical applications using NGS platforms, including NGS panels for bio-sample authentication, contamination detection and quantification, mouse tumor microenvironment profiling and metagenomic sequencing services for microbiome analysis. Custom NGS services are also available for clients who wish to utilize CrownBio’s expertise and large model biobank.
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,” said Sheng Guo, PhD, head of bioinformatics at CrownBio. “These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services.”
These NGS services are available for client use immediately including our newly launched mouse I/O profiling targeted RNA-seq panel. The panel will allow deep profiling of the immunogenomics of murine tumor-immune interactions through the measurement of 1080 transcripts from a single sample.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005802/en/
Contact information
Media Enquiries:
Richard Pearce
pr@crownbio.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CET | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas
Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CET | Press release
Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa
TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit
Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and
Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CET | Press release
Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve
MANSCAPED™ Continues Its Rapid International Expansion, Launching in Norway and Switzerland14.1.2021 18:00:00 CET | Press release
The booming grooming brand that never sleeps is at it again, wasting no time in the new year to add two new countries to its international roster. MANSCAPED™, theglobal leader in men’s below-the-waist grooming and hygiene announced today its launch into Norway and Switzerland. The addition of these regions follows a successful 2020 filled with unprecedented expansion into more than 30 countries across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005831/en/ The premier and leading brand in below-the-waist grooming and hygiene announces exciting expansion. (Graphic: Business Wire) “Our launch into Norway and Switzerland rounds out MANSCAPED’s regional European expansion, which is a true milestone for the brand,” said Casey Gee, Senior International Business Manager at MANSCAPED. “We’re proud to augment our European presence and can’t wait to get our products into the hands of this new set of sharp and savvy
Tigo Energy Raises $20 Million in Funding14.1.2021 17:33:00 CET | Press release
Tigo Energy, Inc., the worldwide leader in Flex-MLPE (Module Level Power Electronics) today announced a $20 million round of investment, led by Energy Growth Momentum. “2020 has been a breakout year for Tigo and 2021 has the potential for even greater success,” stated Zvi Alon, Chairman and CEO of Tigo. “We are excited to have the EG Momentum team’s support and their working capital will enable us to better serve our current customer base and invest in the future expansion with new customers, new partners and new projects.” The investment will be used to improve upon existing products and develop next generation solutions that maximize returns for PV customers. A portion of the new funds will be used to efficiently and effectively scale. Tigo’s growth has accelerated significantly recently as the company’s products have reached more customer segments and countries throughout the world. With over 40,000 installations in over 100 countries on all 7 continents, Tigo systems generate more